CSL is cutting around 1,800 jobs worldwide as part of a sweeping overhaul aimed at streamlining its operations. The move marks one of the largest workforce reductions in the Australian biotech giant’s history.
Furthermore, the Australian biotech giant CSL will spin off its vaccine arm, CSL Seqirus, into a separately listed company by June next year. The shake-up is aimed at simplifying the business and sharpening focus on its core blood-plasma operations. Additionally, it is expected to deliver annualised savings of up to $550 million over three years.
The layoffs will roll out over the next two years, affecting staff across geographies and business units. CSL said the restructuring is designed to sharpen focus on its core therapies and improve operational efficiency in an increasingly competitive global market.
The cuts are expected to weigh most heavily on corporate and administrative functions, though some roles in research and manufacturing will also be impacted. Employees have been notified of the changes, and the company has committed to providing transition support, including redeployment opportunities where possible.
CSL employs more than 30,000 people globally. The job reductions reflect mounting pressure on multinational healthcare firms to adapt quickly to shifting regulatory environments, rising costs, and growing investment in next-generation therapies.
While CSL has emphasised that the restructuring is necessary to maintain long-term competitiveness, the scale of the layoffs underscores the human toll of corporate transformation in the pharmaceutical sector.
